Previous 10 | Next 10 |
Healthcare supplier Lantheus Holdings (NASDAQ:LNTH) has added ~32% in the pre-market Thursday on above-average volume after the company set its outlook ahead of Wall Street forecasts on the back of a strong beat in its Q4 2021 financials. Worldwide revenue for the quarter and f...
Partnership leverages Palette’s specialty sales team to increase promotional footprint of PYLARIFY within the urology call point SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (“Palette”), a global medical de...
Lantheus press release (NASDAQ:LNTH): Q4 Non-GAAP EPS of $0.25 beats by $0.08. Revenue of $129.6M (+37.6% Y/Y) beats by $17.83M. For further details see: Lantheus Non-GAAP EPS of $0.25 beats by $0.08, revenue of $129.6M beats by $17.83M
Worldwide revenue of $129.6 million and $425.2 million for the fourth quarter and full year 2021, representing an increase of 37.6% and an increase of 25.3% over the prior year period, respectively GAAP net loss of $40.2 million and $71.3 million for the fourth quarter and full ...
Lantheus (NASDAQ:LNTH) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is $0.17 (+142.9% Y/Y) and the consensus Revenue Estimate is $111.77M (+18.7% Y/Y). Over the last 2 years, LNTH has beaten EPS estimates 88% of the ti...
On-site plant will produce DEFINITY ® (Perflutren Lipid Microsphere), the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms NORTH BILLERICA, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”...
Healthcare is relatively well-positioned as a defensive sector in a volatile market environment compared to the broader market. Favorable trends to continue boosting healthcare spending. Medical Services and Pharmaceuticals are a few that are better-positioned, while biotechs face...
NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to fin...
NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 24, 2022, to discuss its financial and operating results f...
NORTH BILLERICA, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelli...
News, Short Squeeze, Breakout and More Instantly...
Lantheus Holdings Inc. Company Name:
LNTH Stock Symbol:
NASDAQ Market:
Lantheus Holdings Inc. Website:
2024-08-01 08:00:12 ET David Turkaly from JMP Securities issued a price target of $125.00 for LNTH on 2024-08-01 07:13:00. The adjusted price target was set to $125.00. At the time of the announcement, LNTH was trading at $104.83. The overall price target consensus is at...
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully ...
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 31, 2024, to discuss its financial and operating results for the second...